OR WAIT null SECS
OmniComm Systems, Inc. (OTC BB: OMCM), one of the fastest growing companies in the EDC marketplace, announced today that the company's TrialMaster Phase I Electronic Data Collection (EDC) application has been enhanced to include the integration of patient diaries.
FT. LAUDERDALE, FL -- (MARKET WIRE) -- 05/23/2005 -- OmniComm Systems, Inc. (OTC BB: OMCM), one of the fastest growing companies in the EDC marketplace, announced today that the company's TrialMaster Phase I Electronic Data Collection (EDC) application has been enhanced to include the integration of patient diaries.
This enhancement allows vendor independent patient diary information to be automatically entered into the TrialMaster Phase I EDC system. The TrialMaster Phase I EDC system is used for the collection and primary validation of clinical trial information. The new patient diary integration capability joins the list of available features such as laboratory data import and on-demand export that make TrialMaster's data handling efficient and accurate.
"Our TrialMaster EDC system used in later phase studies has had this functionality for quite some time," stated Randy Smith, CTO of OmniComm. "Due to its flexible nature it was easy for us to add this functionality to the Phase I product at the request of a number of our Phase I clients."
About OmniComm Systems, Inc.
OmniComm Systems, Inc. (www.omnicomm.com) is one of the fastest growing companies in the EDC market place targeting its product TrialMaster to the pharmaceutical, medical device and biotechnology companies as well as CROs. OmniComm's growing base of satisfied customers is a direct result of OmniComm's employees' commitment to on-time, quality and within budget performance.
The TrialMaster (www.trialmaster.com) system, the core product of OmniComm, provides trial sponsors with a 21 CRF Part 11 compliant Internet-based data and trial management solution that greatly increases the efficiency, security and integrity of clinical research data and thus significantly reduces the time and expense involved in conducting clinical studies.
Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.